Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company engaged in the discovery and development of products for select cancers, is pleased to announce that it has successfully verified the diagnostic value of the colorectal biomarkers acquired from Europroteome AG as part of its intellectual property purchase.
